- Home
- PLMR vs DNLI Comparison
PLMR vs DNLI Comparison
Compare PLMR & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLMR | DNLI |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.6B |
| IPO Year | 2019 | 2017 |
Fundamental Metrics
Financial Performance| Metric | PLMR | DNLI |
|---|---|---|
| Price | $130.81 | $17.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | ★ $156.29 | $31.58 |
| AVG Volume (30 Days) | 221.8K | ★ 1.7M |
| Earning Date | 02-11-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.73 | N/A |
| EPS | ★ 6.40 | N/A |
| Revenue | ★ $778,362,000.00 | N/A |
| Revenue This Year | $270.85 | N/A |
| Revenue Next Year | $21.62 | $3,973.10 |
| P/E Ratio | $20.20 | ★ N/A |
| Revenue Growth | ★ 54.59 | N/A |
| 52 Week Low | $98.42 | $10.57 |
| 52 Week High | $175.85 | $24.35 |
Technical Indicators
Market Signals| Indicator | PLMR | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 52.24 | 50.96 |
| Support Level | $126.69 | $15.34 |
| Resistance Level | $138.00 | $17.95 |
| Average True Range (ATR) | 3.82 | 0.74 |
| MACD | -0.70 | 0.00 |
| Stochastic Oscillator | 32.72 | 72.22 |
Price Performance
Historical ComparisonAbout PLMR Palomar Holdings Inc.
Palomar Holdings Inc that provides property and casualty insurance products to individuals and businesses. provide insurance products serving five categories: Earthquake, Inland Marine and Other Property, Casualty, Fronting, and Crop. Company distribute products through multiple channels, including retail agents, program administrators, wholesale brokers, and partnerships with other insurance companies. The companies Earthquake product generate high premium.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.